

<b>PATENT ASSIGNMENT COVER SHEET</b>
--------------------------------------

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT3275838

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
NANOTHERAPEUTICS, INC.	02/27/2015
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	WHITE OAK GLOBAL ADVISORS, LLC
<b>Street Address:</b>	3 EMBARCADERO CENTER, SUITE 550
<b>City:</b>	SAN FRANCISCO
<b>State/Country:</b>	CALIFORNIA
<b>Postal Code:</b>	94111
<b>PROPERTY NUMBERS Total: 96</b>	
<b>Property Type</b>	<b>Number</b>
Patent Number:	6406745
Patent Number:	7063748
PCT Number:	US0301065
PCT Number:	US0300040
PCT Number:	US0311488
Patent Number:	8501232
PCT Number:	US0506579
Patent Number:	7829105
Patent Number:	7846459
PCT Number:	US0625918
Patent Number:	8074906
PCT Number:	US0810318
Patent Number:	8377479
Application Number:	13741915
PCT Number:	US0954130
Patent Number:	7705135
Patent Number:	7691986
PCT Number:	US1999011133
PCT Number:	US9910335
Patent Number:	5929051

PATENT

Property Type	Number
Patent Number:	7022683
Patent Number:	6274548
PCT Number:	US0205974
PCT Number:	US0416146
Patent Number:	6777000
Patent Number:	7494669
PCT Number:	US0725487
PCT Number:	US0517121
PCT Number:	US2005035935
Patent Number:	7488736
Patent Number:	7407966
Patent Number:	7576211
Patent Number:	7598265
Patent Number:	7982040
PCT Number:	US0966589
Patent Number:	8114894
PCT Number:	US0412856
Application Number:	12387226
PCT Number:	US0317709
Patent Number:	7317001
Patent Number:	5247997
Patent Number:	5539087
Patent Number:	6720305
Patent Number:	7273714
PCT Number:	US2005010152
Patent Number:	7605137
PCT Number:	US2005033641
Patent Number:	7405317
PCT Number:	US2004015547
Patent Number:	6855695
Patent Number:	8026095
PCT Number:	US0023242
Patent Number:	6962696
Patent Number:	7452531
PCT Number:	US9809803
Patent Number:	5869676
PCT Number:	US9809750
Patent Number:	5767134

<b>Property Type</b>	<b>Number</b>
<b>PCT Number:</b>	US0132085
<b>Patent Number:</b>	6458816
<b>Patent Number:</b>	6005097
<b>Application Number:</b>	60352322
<b>Application Number:</b>	61089568
<b>Application Number:</b>	60571582
<b>Application Number:</b>	60738084
<b>Application Number:</b>	61119538
<b>Application Number:</b>	60465757
<b>Application Number:</b>	60408596
<b>Application Number:</b>	60469803
<b>Application Number:</b>	61372184
<b>Application Number:</b>	60660738
<b>Application Number:</b>	60663454
<b>Application Number:</b>	60157500
<b>Application Number:</b>	60157581
<b>Application Number:</b>	60157637
<b>Application Number:</b>	60240529
<b>Application Number:</b>	60931528
<b>Application Number:</b>	61128975
<b>Application Number:</b>	60549950
<b>Application Number:</b>	60551981
<b>Application Number:</b>	60549598
<b>Application Number:</b>	60660357
<b>Application Number:</b>	60660356
<b>Application Number:</b>	60781866
<b>Application Number:</b>	60906896
<b>Application Number:</b>	60611623
<b>Application Number:</b>	60615419
<b>Application Number:</b>	60616500
<b>Application Number:</b>	60670308
<b>Application Number:</b>	60157620
<b>Application Number:</b>	61150928
<b>Application Number:</b>	60352259
<b>Application Number:</b>	61948085
<b>Application Number:</b>	61980370
<b>PCT Number:</b>	US1997009486
<b>Application Number:</b>	13827667

**CORRESPONDENCE DATA****Fax Number:**

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

**Phone:** (415) 278-9024  
**Email:** landwebe@chapman.com  
**Correspondent Name:** JOSEPH LANDWEBER  
**Address Line 1:** 595 MARKET STREET, 26TH FLOOR  
**Address Line 4:** SAN FRANCISCO, CALIFORNIA 94105

<b>NAME OF SUBMITTER:</b>	JOSEPH LANDWEBER
---------------------------	------------------

<b>SIGNATURE:</b>	/Joseph Landweber/
-------------------	--------------------

<b>DATE SIGNED:</b>	03/20/2015
---------------------	------------

**Total Attachments: 22**

source=3766959#page1.tif  
source=3766959#page2.tif  
source=3766959#page3.tif  
source=3766959#page4.tif  
source=3766959#page5.tif  
source=3766959#page6.tif  
source=3766959#page7.tif  
source=3766959#page8.tif  
source=3766959#page9.tif  
source=3766959#page10.tif  
source=3766959#page11.tif  
source=3766959#page12.tif  
source=3766959#page13.tif  
source=3766959#page14.tif  
source=3766959#page15.tif  
source=3766959#page16.tif  
source=3766959#page17.tif  
source=3766959#page18.tif  
source=3766959#page19.tif  
source=3766959#page20.tif  
source=3766959#page21.tif  
source=3766959#page22.tif

### RECORDATION FORM COVER SHEET PATENTS ONLY

To the Director of the U.S. Patent and Trademark Office: Please record the attached documents or the new address(es) below.

**1. Name of conveying party(ies)**  
  
Nanotherapeutics, Inc.  
  
Additional name(s) of conveying party(ies) attached?  Yes  No

**2. Name and address of receiving party(ies)**  
Name: White Oak Global Advisors, LLC  
Internal Address: \_\_\_\_\_  
Street Address: 3 Embarcadero Center, Suite 550  
City: San Francisco  
State: California  
Country: USA Zip: 94111  
Additional name(s) & address(es) attached?  Yes  No

**3. Nature of conveyance/Execution Date(s):**  
Execution Date(s) February 27, 2015  
 Assignment  Merger  
 Security Agreement  Change of Name  
 Joint Research Agreement  
 Government Interest Assignment  
 Executive Order 9424, Confirmatory License  
 Other \_\_\_\_\_


**4. Application or patent number(s):**  This document is being filed together with a new application.  
A. Patent Application No.(s)  
See Schedule A attached hereto  
Additional numbers attached?  Yes  No

B. Patent No.(s)  
See Schedule A attached hereto

**5. Name and address to whom correspondence concerning document should be mailed:**  
Name: Joseph Landweber  
Internal Address: \_\_\_\_\_  
Street Address: Chapman and Cutler LLP  
595 Market Street, 26th Floor  
City: San Francisco  
State: California Zip: 94105  
Phone Number: (415) 278-9024  
Docket Number: \_\_\_\_\_  
Email Address: landwebe@chapman.com

**6. Total number of applications and patents involved:** 96  
**7. Total fee (37 CFR 1.21(h) & 3.41)** \$0.00  
 Authorized to be charged to deposit account  
 Enclosed  
 None required (government interest not affecting title)

**8. Payment Information**  
Deposit Account Number \_\_\_\_\_  
Authorized User Name \_\_\_\_\_

**9. Signature:**  3/20/2015  
Signature Date  
Joseph Landweber  
Name of Person Signing  
Total number of pages including cover sheet, attachments, and documents: 22

Documents to be recorded (including cover sheet) should be faxed to (571) 273-0140, or mailed to:  
Mail Stop Assignment Recordation Services, Director of the USPTO, P.O.Box 1450, Alexandria, V.A. 22313-1450

Schedule A to Patent Cover Sheet

1. Patent #:6406745
2. Patent #:7063748
3. PCT #:US0301065
4. PCT #:US0300040
5. PCT #:US0311488
6. Patent #:8501232
7. PCT #:US0506579
8. Patent #:7829105
9. Patent #:7846459
10. PCT #:US0625918
11. Patent #:8074906
12. PCT #:US0810318
13. Patent #:8377479
14. Application #:13741915
15. PCT #:US0954130
16. Patent #:7705135
17. Patent #:7691986
18. PCT #:US1999011133
19. PCT #:US9910335
20. Patent #:5929051
21. Patent #:7022683
22. Patent #:6274548
23. PCT #:US0205974
24. PCT #:US0416146
25. Patent #:6777000
26. Patent #:7494669
27. PCT #:US0725487
28. PCT #:US0517121
29. PCT #:US2005035935
30. Patent #:7488736
31. Patent #:7407966
32. Patent #:7576211
33. Patent #:7598265
34. Patent #:7982040
35. PCT #:US0966589
36. Patent #:8114894
37. PCT #:US0412856

38. Application #:12387226
39. PCT #:US0317709
40. Patent #:7317001
41. Patent #:5247997
42. Patent #:5539087
43. Patent #:6720305
44. Patent #:7273714
45. PCT #:US2005010152
46. Patent #:7605137
47. PCT #:US2005033641
48. Patent #:7405317
49. PCT #:US2004015547
50. Patent #:6855695
51. Patent #:8026095
52. PCT #:US0023242
53. Patent #:6962696
54. Patent #:7452531
55. PCT #:US9809803
56. Patent #:5869676
57. PCT #:US9809750
58. Patent #:5767134
59. PCT #:US0132085
60. Patent #:6458816
61. Patent #:6005097
62. Application #:60352322
63. Application #:61089568
64. Application #:60571582
65. Application #:60738084
66. Application #:61119538
67. Application #:60465757
68. Application #:60408596
69. Application #:60469803
70. Application #:61372184
71. Application #:60660738
72. Application #:60663454
73. Application #:60157500
74. Application #:60157581
75. Application #:60157637

76. Application #:60240529
77. Application #:60931528
78. Application #:61128975
79. Application #:60549950
80. Application #:60551981
81. Application #:60549598
82. Application #:60660357
83. Application #:60660356
84. Application #:60781866
85. Application #:60906896
86. Application #:60611623
87. Application #:60615419
88. Application #:60616500
89. Application #:60670308
90. Application #:60157620
91. Application #:61150928
92. Application #:60352259
93. Application #:61948085
94. Application #:61980370
95. PCT #:US1997009486
96. Application #:13827667



**PATENT SECURITY AGREEMENT**

This PATENT SECURITY AGREEMENT (as amended, supplemented and/or otherwise modified from time to time, this "Agreement"), dated as of February 27, 2015, is between NANOTHERAPEUTICS, INC., a Delaware corporation (the "Grantor"), and WHITE OAK GLOBAL ADVISORS, LLC, a Delaware limited liability company ("Administrative Agent"), as Administrative Agent for the benefit of the Lenders party to that certain Loan Agreement (as hereinafter defined).

**R E C I T A L S**

A. Grantor has entered into or is in the process of entering into that certain Loan and Security Agreement, dated as of February 27, 2015 (as amended, supplemented and/or otherwise modified from time to time, the "Loan Agreement"), among Grantor and Nano ADM, LLC, a Delaware limited liability company as Borrowers, the entities from time to time party thereto as guarantors, the several entities from time to time party thereto as lenders (collectively, "Lenders"), and Administrative Agent, pursuant to which Lenders have agreed, subject to certain terms and conditions, to extend various financial accommodations to Grantor.

B. Pursuant to the Loan Agreement, Grantor grants, pledges and assigns to Administrative Agent for the benefit of the Lenders a security interest in, among other assets, the Intellectual Property (as defined in the Loan Agreement) owned by Grantor.

C. Grantor has duly authorized the execution, delivery and performance of this Agreement.

NOW THEREFORE, for good and valuable consideration (the receipt and sufficiency of which are hereby acknowledged), and in order to induce Lenders to extend credit to Grantor pursuant to the Loan Agreement, Grantor agrees, for the benefit of Administrative Agent, as follows:

*Section 1. Definitions.* Unless the context otherwise requires, each capitalized term used but not otherwise defined herein has the meaning ascribed thereto in the Loan Agreement.

*Section 2. Grant of Security Interest.* For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, to secure the prompt payment and performance when due of all of the Obligations, Grantor hereby grants, pledges and assigns a security interest to Administrative Agent in and to, all of the following, whether now owned or hereafter acquired (collectively, the "Patent Collateral"):

(a) all letters patent of the United States or any other country, all registrations and recordings thereof, and all applications for letters patent of the United States or any other country, including registrations, recordings and applications in the United States Patent and Trademark Office or in any similar office or agency of the United States, any State or Territory thereof, or any other country, including without limitation, those patents and patent applications listed on **Schedule A** attached hereto (all of the foregoing are sometimes hereinafter individually and/or collectively referred to as the "Patents");

(b) subject to the terms of the Loan Agreement, all rights under or interest in any patent license agreements with any other party, if any, whether Grantor is a licensee or licensor under any such license agreement, except to the extent where such grant, pledge or assignment is a breach or causes a modification to, or would breach or cause a modification to, with notice, passage of time or both, the terms and conditions of such patent license agreement (all of the foregoing are hereinafter referred to collectively as the "*Patent Licenses*"); and

(c) all income, royalties, damages, payments and proceeds at any time due or payable to Grantor under and with respect to any of the foregoing, including, without limitation, all of Grantor's rights to sue and recover at law or in equity for any past, present and future infringement, misappropriation, dilution, violation or other impairment thereof, subject to the terms of any patent license or other similar agreement, as the case may be.

*Section 3. New Patents.* If, before the Obligations shall have been paid in full, Grantor shall obtain rights to any new Patents or Patent Licenses, the provisions of **Section 2** shall automatically apply thereto. Grantor shall promptly update **Schedule A** attached hereto as necessary, but no more frequently than once per fiscal quarter, and provide written notice to Administrative Agent of such updates on a fiscal quarterly basis. Grantor authorizes Administrative Agent to modify this Agreement by amending **Schedule A** attached hereto to reflect such updates.

*Section 4. Administrative Agent's Right to Sue.* Grantor shall have the right to bring any opposition proceedings, interferences, cancellation proceedings, or lawsuits in its own name to enforce or protect the Patents, provided that during the continuance of an Event of Default, Grantor shall seek the prior written consent of Administrative Agent, which will not be unreasonably withheld or delayed, in which event Administrative Agent may, if necessary, be joined or named as a nominal party to such suit if Administrative Agent shall have been satisfied that it is not thereby incurring or has been adequately indemnified against any risk of liability because of such joinder. Grantor hereby agrees that, notwithstanding anything to the contrary contained herein or in the Loan Documents, as between Grantor and Administrative Agent, Grantor shall assume full and complete responsibility for the prosecution, defense, enforcement or any other necessary or desirable actions in connection with all or any of the Patent Collateral so long as Grantor is the owner of such Patent Collateral. Grantor shall promptly, upon demand, reimburse and indemnify Administrative Agent for all damages, costs, and expenses, including attorneys' fees, incurred by Administrative Agent in the fulfillment of the provisions of this **Section 4**.

*Section 5. Loan Agreement.* This Agreement has been executed and delivered by Grantor for the purpose of registering the security interest of Administrative Agent in the Patent Collateral with the United States Patent and Trademark Office. The security interest granted hereby has been granted as a supplement to, and not in limitation of, the security interest granted to Lenders under the Loan Agreement. The Loan Agreement (and all rights and remedies of Administrative Agent and each Lender thereunder) shall remain in full force and effect in accordance with its terms and is incorporated herein by this reference.

*Section 6. Release of Security Interest.* Upon the payment in full of the Obligations or otherwise in accordance with the terms of the Loan Agreement, the Patent Collateral shall be released from the security interest granted hereby and in the Loan Agreement and all obligations of Grantor hereunder shall terminate, all without delivery of any instrument or performance of any act by any party,

and all right, title and interest in and to the Patent Collateral shall revert to Grantor. At the request and expense of Grantor, Administrative Agent shall promptly execute and deliver to Grantor all instruments and other documents as may be reasonably necessary to release the security interest in and to the Patent Collateral that has been granted hereunder.

*Section 7. Acknowledgment.* Grantor does hereby further acknowledge and affirm that the rights and remedies of Administrative Agent with respect to the security interest in the Patent Collateral granted hereby are more fully set forth in the Loan Agreement, the terms and provisions of which (including the remedies provided for therein) are incorporated herein by this reference.

*Section 8. Loan Document.* This Agreement is a Loan Document executed pursuant to the Loan Agreement and shall (unless otherwise expressly indicated herein) be construed, administered and applied in accordance with the terms and provisions of the Loan Agreement.

*Section 9. Counterparts.* This Agreement may be executed in counterparts (and by the different parties hereto in different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract.

*Section 10. GOVERNING LAW; JURISDICTION; ETC.*

(a) *GOVERNING LAW.* THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF CALIFORNIA.

(b) *SUBMISSION TO JURISDICTION.* EACH OF THE PARTIES HERETO IRREVOCABLY AND UNCONDITIONALLY SUBMITS, FOR ITSELF AND ITS PROPERTY, TO THE NONEXCLUSIVE JURISDICTION OF THE COURTS OF THE STATE OF CALIFORNIA SITTING IN THE CITY AND COUNTY OF SAN FRANCISCO AND OF THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF CALIFORNIA, AND ANY APPELLATE COURT FROM ANY THEREOF, IN ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT TO WHICH EACH IS A PARTY, OR FOR RECOGNITION OR ENFORCEMENT OF ANY JUDGMENT, AND EACH OF THE PARTIES HERETO IRREVOCABLY AND UNCONDITIONALLY AGREES THAT ALL CLAIMS IN RESPECT OF ANY SUCH ACTION OR PROCEEDING MAY BE HEARD AND DETERMINED IN SUCH STATE COURTS OR, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAWS, IN SUCH FEDERAL COURTS. EACH OF THE PARTIES HERETO AGREES THAT A FINAL JUDGMENT IN ANY SUCH ACTION OR PROCEEDING SHALL BE CONCLUSIVE AND MAY BE ENFORCED IN OTHER JURISDICTIONS BY SUIT ON THE JUDGMENT OR IN ANY OTHER MANNER PROVIDED BY LAW. NOTHING IN THIS AGREEMENT OR IN ANY OTHER LOAN DOCUMENT SHALL AFFECT ANY RIGHT THAT ADMINISTRATIVE AGENT OR ANY LENDER MAY OTHERWISE HAVE TO BRING ANY ACTION OR PROCEEDING RELATING TO THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT AGAINST ANY LOAN PARTY OR ANY OF ITS PROPERTIES IN THE COURTS OF ANY OTHER JURISDICTION.

(c) *WAIVER OF VENUE.* EACH OF THE PARTIES HERETO IRREVOCABLY AND UNCONDITIONALLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAWS, ANY OBJECTION THAT IT MAY NOW OR HEREAFTER HAVE TO THE LAYING OF VENUE OF ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT IN ANY COURT REFERRED TO IN SUBSECTION (B) OF THIS SECTION 10. EACH OF THE PARTIES HERETO HEREBY

IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAWS, THE DEFENSE OF AN INCONVENIENT FORUM TO THE MAINTENANCE OF SUCH ACTION OR PROCEEDING IN ANY SUCH COURT.

(d) *SERVICE OF PROCESS.* EACH PARTY HERETO IRREVOCABLY CONSENTS TO SERVICE OF PROCESS IN THE MANNER PROVIDED FOR NOTICES IN SECTION 10.02 OF THE LOAN AGREEMENT. NOTHING IN THIS AGREEMENT WILL AFFECT THE RIGHT OF ANY PARTY HERETO TO SERVE PROCESS IN ANY OTHER MANNER PERMITTED BY APPLICABLE LAWS.

*Section 11. WAIVER OF RIGHT TO JURY TRIAL.*

TO THE EXTENT PERMITTED BY APPLICABLE LAW, EACH OF THE PARTIES HERETO HEREBY WAIVES ITS RIGHT TO A JURY TRIAL OF ANY CLAIM. EACH OF THE PARTIES HERETO REPRESENTS THAT EACH HAS REVIEWED THIS WAIVER AND EACH KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL ON SUCH MATTERS. IN THE EVENT OF LITIGATION, A COPY OF THIS AGREEMENT MAY BE FILED AS A WRITTEN CONSENT TO A TRIAL BY THE COURT.

IN THE EVENT THAT ANY SUCH ACTION IS COMMENCED OR MAINTAINED IN ANY COURT IN THE STATE OF CALIFORNIA, AND THE WAIVER OF JURY TRIAL SET FORTH ABOVE IS NOT ENFORCEABLE, AND EACH PARTY TO SUCH ACTION DOES NOT SUBSEQUENTLY WAIVE IN AN EFFECTIVE MANNER UNDER CALIFORNIA LAW ITS RIGHT TO A TRIAL BY JURY, THE PARTIES HERETO HEREBY ELECT TO PROCEED AS FOLLOWS:

THE PARTIES AGREE, AND HEREBY AGREE TO ADVISE THE APPLICABLE COURT, THAT THE ADJUDICATION OF ANY SUCH ACTION OR PROCEEDING (AND ALL RELATED CLAIMS) SHALL BE MADE PURSUANT TO CALIFORNIA CODE OF CIVIL PROCEDURE SECTION 638 BY A REFEREE (WHO SHALL BE A SINGLE ACTIVE OR RETIRED JUDGE) WHO SHALL HEAR AND DETERMINE ALL OF THE ISSUES IN SUCH ACTION OR PROCEEDING (WHETHER OF FACT OR OF LAW) AND REPORT A STATEMENT OF DECISION, PROVIDED THAT, AT THE OPTION OF ANY PARTY TO SUCH PROCEEDING, ANY SUCH ISSUES PERTAINING TO A "PROVISIONAL REMEDY" (AS DEFINED IN CALIFORNIA CODE OF CIVIL PROCEDURE SECTION 1281.8), AND ANY NON-JUDICIAL FORECLOSURE OF ANY SECURITY INTERESTS IN REAL OR PERSONAL PROPERTY, THE EXERCISE OF SELF HELP REMEDIES (INCLUDING SET-OFF), THE APPOINTMENT OF A RECEIVER SHALL BE HEARD AND DETERMINED BY THE COURT; AND (B) WITHOUT LIMITING THE GENERALITY OF SECTION 10.04, BORROWERS SHALL BE SOLELY RESPONSIBLE TO PAY ALL FEES AND EXPENSES OF ANY REFEREE APPOINTED IN SUCH ACTION OR PROCEEDING.

THE REFEREE SHALL BE AN ACTIVE OR RETIRED JUDGE OR JUSTICE SELECTED BY MUTUAL WRITTEN AGREEMENT OF THE PARTIES. IF THE PARTIES DO NOT AGREE WITHIN TEN (10) DAYS OF A WRITTEN REQUEST TO DO SO BY ANY PARTY, THEN, UPON REQUEST OF ANY PARTY, THE REFEREE SHALL BE SELECTED BY THE PRESIDING JUDGE OF THE COURT (OR HIS OR HER REPRESENTATIVE). A REQUEST FOR APPOINTMENT OF A REFEREE MAY BE HEARD ON AN EX PARTE OR EXPEDITED BASIS, AND THE PARTIES AGREE THAT IRREPARABLE HARM WOULD RESULT IF EX PARTE RELIEF IS NOT GRANTED.

THE REFEREE SHALL BE REQUIRED TO DETERMINE ALL ISSUES IN ACCORDANCE WITH EXISTING APPLICABLE CASE LAW AND STATUTORY LAW. THE RULES OF EVIDENCE APPLICABLE TO PROCEEDINGS

AT LAW IN THE COURT WILL BE APPLICABLE TO THE REFERENCE PROCEEDING. THE REFEREE SHALL BE EMPOWERED TO ENTER EQUITABLE AS WELL AS LEGAL RELIEF, ENTER EQUITABLE ORDERS THAT WILL BE BINDING ON THE PARTIES AND RULE ON ANY MOTION THAT WOULD BE AUTHORIZED IN A COURT PROCEEDING. THE REFEREE SHALL ISSUE A DECISION AT THE CLOSE OF THE REFERENCE PROCEEDING THAT DISPOSES OF ALL CLAIMS OF THE PARTIES THAT ARE THE SUBJECT OF THE REFERENCE. PURSUANT TO CALIFORNIA CODE OF CIVIL PROCEDURE SECTION 644, SUCH DECISION SHALL BE ENTERED BY THE COURT AS A JUDGMENT OR AN ORDER IN THE SAME MANNER AS IF THE ACTION HAD BEEN TRIED BY THE COURT AND ANY SUCH DECISION WILL BE FINAL, BINDING AND CONCLUSIVE. THE PARTIES RESERVE THE RIGHT TO APPEAL FROM THE FINAL JUDGMENT OR ORDER OR FROM ANY APPEALABLE DECISION OR ORDER ENTERED BY THE REFEREE. THE PARTIES RESERVE THE RIGHT TO FINDINGS OF FACT, CONCLUSIONS OF LAWS, A WRITTEN STATEMENT OF DECISION, AND THE RIGHT TO MOVE FOR A NEW TRIAL OR A DIFFERENT JUDGMENT, WHICH NEW TRIAL, IF GRANTED, IS ALSO TO BE A REFERENCE PROCEEDING UNDER THIS PROVISION.

[SIGNATURE PAGE FOLLOWS.]

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed and delivered by their respective officers thereunto duly authorized as of the day and year first written above.

WHITE OAK GLOBAL ADVISORS, LLC,  
as Administrative Agent

NANOTHERAPEUTICS, INC.,  
as Grantor

By: *Barbara J. S. McKee*  
Name: Barbara J.S. McKee  
Title: Managing Member

By: \_\_\_\_\_  
Name: \_\_\_\_\_  
Title: \_\_\_\_\_


*Patent Security Agreement*

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed and delivered by their respective officers thereunto duly authorized as of the day and year first written above.

WHITE OAK GLOBAL ADVISORS, LLC,  
as Administrative Agent

By: \_\_\_\_\_  
Name: \_\_\_\_\_  
Title: Managing Member

NANOTHERAPEUTICS, INC.,  
as Grantor

By:  \_\_\_\_\_  
Name: LEITH WOOD  
Title: PRESIDENT CEO

*Patent Security Agreement (Nano)*

**SCHEDULE A  
TO PATENT SECURITY AGREEMENT**

**SEE ATTACHED**



3/20/2015

Product/Technology Codes

NanoCOAT:	NC	NanoFUSE:	NF
NanoBREATH:	NB	NanoQUAD:	NQ
DEAD:	DEAD	NanoBIP:	NBIP
NanoDRY:	ND	NanoDOX:	NDOX
GELSITE:	GELSITE	VION:	VION
PRX 3140:	PRX 3140	Chlorzaxine:	CLOR
Ramoplanin:	RAMO	Tapet:	TAPET
NCL Vaccines:	NCL	Tripline:	TRI
FDAC:	FDAC	Provisional:	Provisional

Product/ Tech Codes	Case/subcase	Case/Type	Application/Status	Appl. No.	Patent No.	File Date	Country/Name	Issue Date	Applite	Assignee
NC	08100-000100110	PCT	Abandoned	54669/00	7794/7	4-Dec-2001	Australia	02-Jun-2005	METHODS FOR COATING PARTICLES AND PARTICLES PRODUCED THEREBY	NANOSPHERE, INC
NC	08100-000101110	DIV	Abandoned	2005201/57	2005201/57	27-Apr-2005	Australia	06-Sep-2007	METHODS FOR COATING PARTICLES AND PARTICLES PRODUCED THEREBY	NANOTHERAPEUTICS, INC
NC	08100-000100	PCT	Abandoned	P0011129/4		6-Jun-2000	Brazil		METHODS FOR COATING PARTICLES AND PARTICLES PRODUCED THEREBY	NANOSPHERE, INC
NC	08100-000100	PCT	Abandoned	33761/3		6-Jun-2000	Canada		METHODS FOR COATING PARTICLES AND PARTICLES PRODUCED THEREBY	NANOSPHERE, INC
NC	08100-000100	PCT	Abandoned	806978/8		6-Jun-2000	China		METHODS FOR COATING PARTICLES AND PARTICLES PRODUCED THEREBY	NANOSPHERE, INC
NC	08100-000100	PCT	Abandoned	P12001-43/9		6-Jun-2000	Czech Republic		METHODS FOR COATING PARTICLES AND PARTICLES PRODUCED THEREBY	NANOSPHERE, INC
NC	08100-000100	PCT	Abandoned	93890/3		6-Jun-2000	Europe		METHODS FOR COATING PARTICLES AND PARTICLES PRODUCED THEREBY	NANOSPHERE, INC
NC	08100-000100	PCT	Abandoned	2107/18		6-Jun-2000	Hong Kong		METHODS FOR COATING PARTICLES AND PARTICLES PRODUCED THEREBY	NANOSPHERE, INC
NC	08100-000100	PCT	Abandoned	P201645		6-Jun-2000	Hungary		METHODS FOR COATING PARTICLES AND PARTICLES PRODUCED THEREBY	NANOSPHERE, INC
NC	08100-000100187	PCT	Abandoned	INPCT/2001/01224	208413	6-Jun-2000	India	26-Jul-2007	METHODS FOR COATING PARTICLES AND PARTICLES PRODUCED THEREBY	NANOSPHERE, INC
NC	08100-000100	PCT	Abandoned	148808		29-Nov-2001	Israel		METHODS FOR COATING PARTICLES AND PARTICLES PRODUCED THEREBY	NANOSPHERE, INC
NC	08100-000100	PCT	Abandoned	2001901/94		6-Jun-2000	Japan		METHODS FOR COATING PARTICLES AND PARTICLES PRODUCED THEREBY	NANOTHERAPEUTICS, INC
NC	08100-000100195	PCT	Abandoned	1.02007E+12		6-Jun-2000	Korea		METHODS FOR COATING PARTICLES AND PARTICLES PRODUCED THEREBY	NANOSPHERE, INC
NC	08100-000100	PCT	Abandoned	20010129588		6-Jun-2000	Mexico		METHODS FOR COATING PARTICLES AND PARTICLES PRODUCED THEREBY	NANOSPHERE, INC
NC	08100-000100234	PCT	Pending	515648	515648	6-Jun-2000	New Zealand	08-Jun-2004	METHODS FOR COATING PARTICLES AND PARTICLES PRODUCED THEREBY	NANOSPHERE, INC
NC	08100-000100	PCT	Abandoned	200159395		6-Jun-2000	Norway		METHODS FOR COATING PARTICLES AND PARTICLES PRODUCED THEREBY	NANOSPHERE, INC
NC	08100-000100	ORD	Completed	No		6-Jun-2000	PCT		METHODS FOR COATING PARTICLES AND PARTICLES PRODUCED THEREBY	NANOSPHERE, INC
NC	08100-000100	PCT	Abandoned	P351665		6-Jun-2000	Poland		METHODS FOR COATING PARTICLES AND PARTICLES PRODUCED THEREBY	NANOSPHERE, INC
NC	08100-000100	PCT	Abandoned	2001135112/14.038525	22850764	6-Jun-2000	Russia	27-Apr-2005	METHODS FOR COATING PARTICLES AND PARTICLES PRODUCED THEREBY	NANOSPHERE, INC
NC	08100-000100235	PCT	Abandoned	200106993/9	84448	6-Jun-2000	Singapore	31-Dec-2003	METHODS FOR COATING PARTICLES AND PARTICLES PRODUCED THEREBY	NANOSPHERE, INC
NC	08100-000100	PCT	Abandoned	2001110390	2001110390	6-Jun-2000	Spain	24-Dec-2002	METHODS FOR COATING PARTICLES AND PARTICLES PRODUCED THEREBY	NANOSPHERE, INC
NC	08100-000100	PCT	Abandoned	200102540	2001-02540	6-Jun-2000	Turkey	21-Apr-2004	METHODS FOR COATING PARTICLES AND PARTICLES PRODUCED THEREBY	NANOTHERAPEUTICS, INC
NC	08100-000100	ORD	Abandoned	090588/208	6406745	6-Jun-2000	U.S.	18-Jun-2002	METHODS FOR COATING PARTICLES AND PARTICLES PRODUCED THEREBY	NANOTHERAPEUTICS, INC
NC	08100-000101	CON	Issued	10056/585	7063748	13-Mar-2002	U.S.	20-Jun-2006	METHODS FOR COATING PARTICLES AND PARTICLES PRODUCED THEREBY	NANOTHERAPEUTICS, INC
NB	08100-0023000	ORD	Completed	PCT/US0301065		29-Jun-2003	PCT		METHOD OF COLLECTING AND ANALYZING HUMAN BREATH	NANOTHERAPEUTICS, INC
NB	08100-0020000	PCT	Abandoned	90008/706	7453272	18-Nov-2004	U.S.	12-Aug-2008	METHOD OF COLLECTING AND ANALYZING HUMAN BREATH	NANOTHERAPEUTICS, INC
NB	08100-0020001	DIV	Abandoned	11657/797		8-Nov-2006	U.S.		APPARATUS FOR COLLECTING AND ANALYZING HUMAN BREATH	NANOTHERAPEUTICS, INC
DEAD	08100-0019000	ORD	Completed	PCT/US0300040		22-Jun-2003	PCT		METHOD OF PULSED LASER ASSISTED SURFACE	NANOTHERAPEUTICS, INC
DEAD	08100-0019000	PCT	Abandoned	10602/022		21-Jul-2004	U.S.		METHOD OF PULSED LASER ASSISTED SURFACE	NANOTHERAPEUTICS, INC
DEAD	08100-0026900	ORD	Abandoned	11636/346		21-Feb-2006	U.S.		Invented cannula for use in reconstituting dry material in syringes	NANOTHERAPEUTICS, INC



GEL SITE	08100-004600	DIV	Abandoned	11/7/3,437			2-Mar-2007	U.S.		Combination of a growth factor and protease enzyme	NANOTHERAPEUTICS, INC.
GEL SITE	08100-004700	CON	Issued	10/422,957	7,591,956		23-Apr-2003	U.S.	06-Apr-2010	High molecular weight, lower molecular weight, and their production and uses	NANOTHERAPEUTICS, INC.
GEL SITE	08100-005000	ORD	Unfiled					U.S.		Reassignment of US Patent No. 7,022,833	
GEL SITE	08100-005100	ORD	Unfiled					U.S.		Reassignment of US Patent No. 8,777,000	
GEL SITE	08100-005200	ORD	Unfiled					U.S.		Reassignment of US Patent No. 6,313,103	
GEL SITE	08100-005300	ORD	Unfiled					U.S.		Reassignment of US Patent No. 5,780,102	
GEL SITE	08100-005900	ORD	Unfiled					U.S.		Reassignment of US Patent No. 5,449,703	
GEL SITE	08100-006000	ORD	Unfiled					U.S.		Reassignment of US Patent No. 5,443,830	
GEL SITE	08100-006100	ORD	Unfiled					U.S.		Reassignment of US Patent No. 5,308,838	
GEL SITE	08100-006200	ORD	Unfiled					U.S.		Reassignment of US Patent No. 5,308,838	
GEL SITE	08100-007001	PCT	Abandoned	233,8307			22-Apr-2001	Canada		PECTIC SUBSTANCE AS A GROWTH FACTOR STABILIZER	NANOTHERAPEUTICS, INC.
GEL SITE	08100-007002	PCT	Issued	233,1744	233,1744		10-Nov-2000	Canada	05-Oct-2010	ALOE PECTINS	NANOTHERAPEUTICS, INC.
GEL SITE	08100-007001	PCT	Abandoned	999,2326,5	1,100,820		20-May-1999	Europe	19-Apr-2006	PECTIC SUBSTANCE AS A GROWTH FACTOR STABILIZER	NANOTHERAPEUTICS, INC.
GEL SITE	08100-007002	DIV	Issued	999,7189,4	1,088,141		30-Nov-2000	Europe	28-Sep-2005	ALOE PECTINS	NANOTHERAPEUTICS, INC.
GEL SITE	08100-007006	DIV	Abandoned	507,100,5			12-May-1999	Europe		PHARMACEUTICAL COMPOSITIONS COMPRISING PECTINS HAVING HIGH MOLECULAR WEIGHTS AND LOW DEGREES OF METHYLATION	NANOTHERAPEUTICS, INC.
GEL SITE	08100-007001	PCT	Abandoned	1,102,564,7	1,034,718		27-Jul-2001	Hong Kong	06-Oct-2006	PECTIC SUBSTANCE AS A GROWTH FACTOR STABILIZER	NANOTHERAPEUTICS, INC.
GEL SITE	08100-007001	PCT	Abandoned	2,000,561,213			22-Apr-2001	Japan		PECTIC SUBSTANCE AS A GROWTH FACTOR STABILIZER	NANOTHERAPEUTICS, INC.
GEL SITE	08100-007002	PCT	Abandoned	2,000,546,377			13-Nov-2000	Japan		ALOE PECTINS	NANOTHERAPEUTICS, INC.
GEL SITE	08100-007002	PCT	Abandoned	10,500,700,089	703,040		20-May-1999	Korea	28-May-2007	PECTIC SUBSTANCE AS A GROWTH FACTOR STABILIZER	NANOTHERAPEUTICS, INC.
GEL SITE	08100-007001	PCT	Abandoned	10,500,701,211	10,507,823		20-May-1999	Korea	30-May-2008	PECTIC SUBSTANCE AS A GROWTH FACTOR STABILIZER	NANOTHERAPEUTICS, INC.
GEL SITE	08100-007001	ORD	Completed	PCT/US99/01133			12-May-1999	PCT		ALOE PECTINS	NANOTHERAPEUTICS, INC.
GEL SITE	08100-007002	ORD	Completed	PCT/US99/0335			13-May-1999	PCT		ALOE PECTINS	NANOTHERAPEUTICS, INC.
GEL SITE	08100-007001	CP	Issued	09/078,204	631,913		24-Apr-1998	U.S.	06-Nov-2001	PECTIC SUBSTANCE AS A GROWTH FACTOR STABILIZER	NANOTHERAPEUTICS, INC.
GEL SITE	08100-007002	CON	Issued	09/255,610	702,893		3-Jun-1999	U.S.	04-Jun-2006	PHARMACEUTICAL COMPOSITIONS COMPRISING PECTINS HAVING HIGH MOLECULAR WEIGHTS AND LOW DEGREES OF METHYLATION	NANOTHERAPEUTICS, INC.
GEL SITE	08100-007003	DIV	Issued	09/255,923	627,458		4-Jun-1999	U.S.	14-Aug-2001	PECTIC SUBSTANCE AS A GROWTH FACTOR STABILIZER	NANOTHERAPEUTICS, INC.
GEL SITE	08100-007005	DIV	Abandoned				19-May-2006	U.S.		PHARMACEUTICAL COMPOSITIONS COMPRISING ALOE PECTINS, AND METHODS FOR THEIR PRODUCTION AND USE	NANOTHERAPEUTICS, INC.
GEL SITE	08100-007001	PCT	Abandoned	200,427,010			1-Mar-2006	Australia		Delivery of physiological agents with in-situ gels comprising anionic polysaccharides	NANOTHERAPEUTICS, INC.
GEL SITE	08100-007101	PCT	Issued	24,957,0	24,957,0		28-Aug-2003	Canada	4/24/2012	Delivery of physiological agents with in-situ gels comprising anionic polysaccharides	NANOTHERAPEUTICS, INC.
GEL SITE	08100-007101	PCT	Issued	253,790			28-Feb-2006	Canada		Delivery of physiological agents with in-situ gels comprising anionic polysaccharides	NANOTHERAPEUTICS, INC.
GEL SITE	08100-007100	PCT	Issued	280,735	21,028,731,5		26-Sep-2003	China	17-May-2008	Delivery of physiological agents with in-situ gels comprising anionic polysaccharides	NANOTHERAPEUTICS, INC.
GEL SITE	08100-007101	PCT	Abandoned	2,004,654,11			28-Feb-2006	China		Delivery of physiological agents with in-situ gels comprising anionic polysaccharides	NANOTHERAPEUTICS, INC.
GEL SITE	08100-007101	PCT	Issued	2,000,600,44	10,951		28-Apr-2006	Europe	19-May-2008	Delivery of physiological agents with in-situ gels comprising anionic polysaccharides	NANOTHERAPEUTICS, INC.
GEL SITE	08100-007101	PCT	Abandoned	2,780,273,9			26-Sep-2003	Europe		In-Situ Gel Formation of Pectins	NANOTHERAPEUTICS, INC.
GEL SITE	08100-007101	PCT	Abandoned	475,044,9			24-May-2004	Europe		Delivery of physiological agents with in-situ gels comprising anionic polysaccharides	NANOTHERAPEUTICS, INC.
GEL SITE	08100-007101	PCT	Abandoned	611,951,2,8			7-Dec-2006	Hong Kong		Delivery of physiological agents with in-situ gels comprising anionic polysaccharides	NANOTHERAPEUTICS, INC.
GEL SITE	08100-007101	PCT	Abandoned	1,693,041,9,200,6			28-May-2006	India		Delivery of physiological agents with in-situ gels comprising anionic polysaccharides	NANOTHERAPEUTICS, INC.
GEL SITE	08100-007100	PCT	Abandoned	2,002,567,265			27-Aug-2003	Japan		In-Situ Gel Formation of Pectins	NANOTHERAPEUTICS, INC.
GEL SITE	08100-007101	PCT	Issued	2,006,434,618	4,765,020		27-Feb-2006	Japan	6/24/2011	Delivery of physiological agents with in-situ gels comprising anionic polysaccharides	NANOTHERAPEUTICS, INC.
GEL SITE	08100-007103	DIV	Abandoned	2,006,434,618			27-Feb-2002	Japan		In-Situ Gel Formation of Pectins	NANOTHERAPEUTICS, INC.
GEL SITE	08100-007100	PCT	Abandoned	10,300,670,11,622			27-Aug-2003	Korea		Delivery of physiological agents with in-situ gels comprising anionic polysaccharides	NANOTHERAPEUTICS, INC.
GEL SITE	08100-007100	ORD	Completed	PCT/US02/05974			28-Feb-2006	Korea		Delivery of physiological agents with in-situ gels comprising anionic polysaccharides	NANOTHERAPEUTICS, INC.
GEL SITE	08100-007101	ORD	Completed	PCT/US04/01416			27-Feb-2002	PCT		Delivery of physiological agents with in-situ gels comprising anionic polysaccharides	NANOTHERAPEUTICS, INC.
GEL SITE	08100-007100	ORD	Issued	09/795,997	677,000		28-Feb-2001	U.S.	17-Aug-2004	In-Situ Gel Formation of Pectins	NANOTHERAPEUTICS, INC.

PATENT

REEL: 035236 FRAME: 0950

GEL SITE	08100-007101	CIP	Issued	10652 822	748699	29-Aug-2003	U.S.	24-Feb-2009	Delivery of physiological agents with in-situ gels comprising anionic poly(saccharides)	NANOTHERAPEUTICS, INC.
GEL SITE	08100-007102	CIP	Abandoned	10652 873		29-Aug-2003	U.S.			
PRX-3140	08100-006900	PCT	Completed	PCT/US07/025487		11-Dec-2007	U.S.		Delivery of physiological agents with in-situ gels comprising anionic polysaccharides	DELR SITE BIOTECHNOLOGIES, INC.
PRX-3140	08100-006901	PCT	Abandoned	6832		13-Sep-2006	Argentina		Therapy/prifone Compounds and Methods of Treatment	EPX DELAWARE, INC.
PRX-3140	08100-006903	PCT	Abandoned	7026		24-Apr-2007	Argentina		Therapy/prifone Compounds and Methods of Treatment	EPX DELAWARE, INC.
PRX-3140	08100-006901	PCT	Abandoned	8030		14-May-2008	Argentina		Therapy/prifone Compounds and Methods of Treatment	EPX DELAWARE, INC.
PRX-3140	08100-006903	ORD	Abandoned	P05104240		6-Oct-2006	Argentina		Compositions and Methods for Treating CNS Disorders	EPX DELAWARE, INC.
PRX-3140	08100-006900	PCT	Issued	2005293632		30-Oct-2006	Australia	6/14/2012	Therapy/prifone Compounds and Methods of Treatment	EPX DELAWARE, INC.
PRX-3140	08100-006901	PCT	Abandoned	200619564		12-Apr-2007	Australia		Therapy/prifone Compounds and Methods of Treatment	EPX DELAWARE, INC.
PRX-3140	08100-006901	PCT	Abandoned	P05100224		16-Nov-2006	Brazil		Therapy/prifone Compounds and Methods of Treatment	EPX DELAWARE, INC.
PRX-3140	08100-006901	PCT	Abandoned	P05161304		9-Apr-2007	Brazil		Therapy/prifone Compounds and Methods of Treatment	EPX DELAWARE, INC.
PRX-3140	08100-006903	PCT	Pending	P06184936		6-Nov-2006	Brazil		Compositions and Methods for Treating CNS Disorders	EPX DELAWARE, INC.
PRX-3140	08100-006901	PCT	Issued	257288		16-Nov-2006	Canada		Therapy/prifone Compounds and Methods of Treatment	EPX DELAWARE, INC.
PRX-3140	08100-006903	PCT	Abandoned	2583353		5-Apr-2007	Canada		Therapy/prifone Compounds and Methods of Treatment	EPX DELAWARE, INC.
PRX-3140	08100-006903	PCT	Issued	2629312		9-May-2008	Canada	8/12/2014	Compositions and Methods for Treating CNS Disorders	EPX DELAWARE, INC.
PRX-3140	08100-006900	PCT	Abandoned	427892		9-Nov-2006	Chile		Therapy/prifone Compounds and Methods of Treatment	EPX DELAWARE, INC.
PRX-3140	08100-006901	ORD	Abandoned	2616-2005		6-Oct-2005	Chile		Therapy/prifone Compounds and Methods of Treatment	EPX DELAWARE, INC.
PRX-3140	08100-006903	ORD	Opposed	350449		4-Apr-2007	Chile		Compositions and Methods for Treating CNS Disorders	EPX DELAWARE, INC.
PRX-3140	08100-006900	PCT	Abandoned	2.0086E+11		24-Nov-2005	China		Therapy/prifone Compounds and Methods of Treatment	EPX DELAWARE, INC.
PRX-3140	08100-006901	PCT	Abandoned	2.0086E+11		15-May-2007	China		Therapy/prifone Compounds and Methods of Treatment	EPX DELAWARE, INC.
PRX-3140	08100-006903	PCT	Abandoned	6.129518		12-Jun-2008	China		Compositions and Methods for Treating CNS Disorders	EPX DELAWARE, INC.
PRX-3140	08100-006900	ORD	Abandoned	07.044.404		4-May-2007	Colombia		Therapy/prifone Compounds and Methods of Treatment	EPX DELAWARE, INC.
PRX-3140	08100-006903	PCT	Abandoned	08.089.972		10-Jun-2008	Colombia		Compositions and Methods for Treating CNS Disorders	EPX DELAWARE, INC.
PRX-3140	08100-006903	PCT	Abandoned	10.028		15-Nov-2006	Costa Rica		Therapy/prifone Compounds and Methods of Treatment	EPX DELAWARE, INC.
PRX-3140	08100-006903	PCT	Abandoned	1089/2006		15-Nov-2006	Egypt		Therapy/prifone Compounds and Methods of Treatment	EPX DELAWARE, INC.
PRX-3140	08100-006901	ORD	Abandoned	349207		8-Apr-2007	Egypt		Therapy/prifone Compounds and Methods of Treatment	EPX DELAWARE, INC.
PRX-3140	08100-006903	PCT	Abandoned	PCT/06/2008		11-May-2008	Egypt		Therapy/prifone Compounds and Methods of Treatment	EPX DELAWARE, INC.
PRX-3140	08100-006903	PCT	Abandoned	200801302		9-Jun-2008	Eurasia		Therapy/prifone Compounds and Methods of Treatment	EPX DELAWARE, INC.
PRX-3140	08100-006901	PCT	Pending	577391.4		15-Nov-2006	Europe		Therapy/prifone Compounds and Methods of Treatment	EPX DELAWARE, INC.
PRX-3140	08100-006901	PCT	Abandoned	560.809.4		3-May-2007	Europe		Therapy/prifone Compounds and Methods of Treatment	EPX DELAWARE, INC.
PRX-3140	08100-006904	PCT	Abandoned	682753.8		6-Nov-2006	Europe		Compositions and Methods for Treating CNS Disorders	EPX DELAWARE, INC.
PRX-3140	08100-006900	ORD	Abandoned	10193700.1		3-Dec-2010	Europe		Therapy/prifone Compounds and Methods of Treatment	EPX DELAWARE, INC.
PRX-3140	08100-006901	ORD	Abandoned	810388.3		4-May-2008	Hong Kong		Therapy/prifone Compounds and Methods of Treatment	EPX DELAWARE, INC.
PRX-3140	08100-006903	PCT	Abandoned	9101544		18-Feb-2009	Hong Kong		Therapy/prifone Compounds and Methods of Treatment	EPX DELAWARE, INC.
PRX-3140	08100-006901	PCT	Pending	42281CHEP/2006		16-Nov-2006	India		Therapy/prifone Compounds and Methods of Treatment	EPX DELAWARE, INC.
PRX-3140	08100-006901	PCT	Abandoned	1933CHEP/2008		7-May-2007	India		Therapy/prifone Compounds and Methods of Treatment	EPX DELAWARE, INC.
PRX-3140	08100-006901	PCT	Abandoned	2966CHEP/2008		10-Jun-2008	India		Compositions and Methods for Treating CNS Disorders	EPX DELAWARE, INC.
PRX-3140	08100-006900	ORD	Abandoned	W12020030219		15-Nov-2006	Indonesia		Therapy/prifone Compounds and Methods of Treatment	EPX DELAWARE, INC.
PRX-3140	08100-006901	ORD	Abandoned	W02020710114		5-Apr-2007	Indonesia		Therapy/prifone Compounds and Methods of Treatment	EPX DELAWARE, INC.
PRX-3140	08100-006903	PCT	Abandoned	W0203090144		6-Nov-2006	Indonesia		Compositions and Methods for Treating CNS Disorders	EPX DELAWARE, INC.
PRX-3140	08100-006900	PCT	Abandoned	170896		1-Nov-2006	Israel		Therapy/prifone Compounds and Methods of Treatment	EPX DELAWARE, INC.
PRX-3140	08100-006901	PCT	Abandoned	182456		6-Oct-2005	Israel		Therapy/prifone Compounds and Methods of Treatment	EPX DELAWARE, INC.

PATENT

REEL: 035236 FRAME: 0951

PRX-3140	08100-006903	PCT	Abandoned	19188		30-Apr-2008	Israel		Compositions and Methods for Treating CNS Disorders	EPIX DELAWARE, INC.
PRX-3140	08100-006900	PCT	Issued	2007-527345	4897893	15-Nov-2006	Japan		Thienopyridone Compounds and Methods of Treatment	EPIX DELAWARE, INC.
PRX-3140	08100-006901	PCT	Abandoned	2007-528001		6-Apr-2007	Japan		Thienopyridone Compounds and Methods of Treatment	EPIX DELAWARE, INC.
PRX-3140	08100-006903195	PCT	Abandoned	2008-540898		9-May-2008	Japan		Compositions and Methods for Treating CNS Disorders	EPIX DELAWARE, INC.
PRX-3140	08100-00690202	PCT	Issued	10-2006-7028904	10-1216286	16-May-2005	Korea		Thienopyridone Compounds and Methods of Treatment	EPIX DELAWARE, INC.
PRX-3140	08100-006901202	PCT	Abandoned	10-2007-7089043		6-Oct-2005	Korea		Thienopyridone Compounds and Methods of Treatment	EPIX DELAWARE, INC.
PRX-3140	08100-006903202	PCT	Abandoned	10-2008-7013112		9-Jun-2008	Korea		Compositions and Methods for Treating CNS Disorders	EPIX DELAWARE, INC.
PRX-3140	08100-006903	ORD	Abandoned	P 20081531		9-May-2008	Malaysia		Compositions and Methods for Treating CNS Disorders	EPIX DELAWARE, INC.
PRX-3140	08100-006901	PCT	Abandoned	MX/02/07/004230		6-Oct-2005	Mexico		Thienopyridone Compounds and Methods of Treatment	EPIX DELAWARE, INC.
PRX-3140	08100-00694223	PCT	Issued	MX/02/01/1012985	277873	9-May-2008	Mexico	05/2010	Compositions and Methods for Treating CNS Disorders	EPIX DELAWARE, INC.
PRX-3140	08100-006904	DNV	Unfiled				Mexico		Compositions and Methods for Treating CNS Disorders	
PRX-3140	08100-006900	PCT	Abandoned	29451	2852	13-Nov-2006	Morocco	02-May-2007	Thienopyridone Compounds and Methods of Treatment	EPIX DELAWARE, INC.
PRX-3140	08100-006901	PCT	Abandoned	29886	29211	4-May-2007	Morocco	01-Feb-2008	Thienopyridone Compounds and Methods of Treatment	EPIX DELAWARE, INC.
PRX-3140	08100-006903	PCT	Abandoned	31013	3113	6-Jun-2008	Morocco	01-Dec-2008	Thienopyridone Compounds and Methods of Treatment	EPIX DELAWARE, INC.
PRX-3140	08100-006900	PCT	Abandoned	550945		27-Oct-2006	New Zealand		Thienopyridone Compounds and Methods of Treatment	EPIX DELAWARE, INC.
PRX-3140	08100-006901	PCT	Abandoned	554927		6-Oct-2005	New Zealand		Thienopyridone Compounds and Methods of Treatment	EPIX DELAWARE, INC.
PRX-3140	08100-006903	PCT	Abandoned	568859		5-Jun-2008	New Zealand		Compositions and Methods for Treating CNS Disorders	EPIX DELAWARE, INC.
PRX-3140	08100-006900	PCT	Abandoned	568859		16-Nov-2005	Nigeria	06-Jun-2008	Thienopyridone Compounds and Methods of Treatment	EPIX DELAWARE, INC.
PRX-3140	08100-006901	PCT	Lapsed	5818114	NG/C/2007/688	6-Apr-2007	Nigeria		Thienopyridone Compounds and Methods of Treatment	EPIX DELAWARE, INC.
PRX-3140	08100-006900	PCT	Abandoned	591875		15-Dec-2006	Nigeria		Compositions and Methods for Treating CNS Disorders	EPIX DELAWARE, INC.
PRX-3140	08100-006903	PCT	Abandoned	NG/C/2009/256		6-Nov-2005	Nigeria		Thienopyridone Compounds and Methods of Treatment	EPIX DELAWARE, INC.
PRX-3140	08100-006902	PCT	Abandoned	20055614		6-Oct-2005	Norway		Thienopyridone Compounds and Methods of Treatment	EPIX DELAWARE, INC.
PRX-3140	08100-006901	PCT	Abandoned	20072348		6-Oct-2005	Norway		Thienopyridone Compounds and Methods of Treatment	EPIX DELAWARE, INC.
PRX-3140	08100-006903	PCT	Abandoned	20082879		10-Jun-2008	Norway		Compositions and Methods for Treating CNS Disorders	EPIX DELAWARE, INC.
PRX-3140	08100-006900	ORD	Abandoned	PCT/US09/17121		16-May-2005	PCT		Thienopyridone Compounds and Methods of Treatment	NANOTHERAPEUTICS, INC.
PRX-3140	08100-006901	ORD	Completed	PCT/US2006/025555		6-Oct-2005	PCT		Thienopyridone Compounds and Methods of Treatment	NANOTHERAPEUTICS, INC.
PRX-3140	08100-006900	PCT	Abandoned	1-2006-502774		15-Nov-2006	Philippines		Thienopyridone Compounds and Methods of Treatment	EPIX DELAWARE, INC.
PRX-3140	08100-006901	PCT	Abandoned	1-2007-500770		10-Apr-2007	Philippines		Thienopyridone Compounds and Methods of Treatment	EPIX DELAWARE, INC.
PRX-3140	08100-006903	PCT	Abandoned	1-2008-501046		2-May-2008	Philippines		Thienopyridone Compounds and Methods of Treatment	EPIX DELAWARE, INC.
PRX-3140	08100-006900	PCT	Abandoned	2006144887		15-Dec-2006	Russia		Thienopyridone Compounds and Methods of Treatment	EPIX DELAWARE, INC.
PRX-3140	08100-006901	PCT	Abandoned	2007115650		6-Oct-2005	Russia		Thienopyridone Compounds and Methods of Treatment	EPIX DELAWARE, INC.
PRX-3140	08100-006900	PCT	Lapsed	92287	127332	16-May-2005	Singapore	30-Jun-2009	Thienopyridone Compounds and Methods of Treatment	EPIX DELAWARE, INC.
PRX-3140	08100-006901	PCT	Lapsed	200702579-4		5-Apr-2007	Singapore		Thienopyridone Compounds and Methods of Treatment	EPIX DELAWARE, INC.
PRX-3140	08100-006903	PCT	Abandoned	283778		6-Nov-2006	Singapore		Compositions and Methods for Treating CNS Disorders	EPIX DELAWARE, INC.
PRX-3140	08100-006900	PCT	Abandoned	200609213	200609213	31-Oct-2007	South Africa		Thienopyridone Compounds and Methods of Treatment	EPIX DELAWARE, INC.
PRX-3140	08100-006901	PCT	Lapsed	200703586		6-Nov-2006	South Africa	28-May-2008	Thienopyridone Compounds and Methods of Treatment	EPIX DELAWARE, INC.
PRX-3140	08100-006901	PCT	Abandoned	200703586		4-May-2007	South Africa		Thienopyridone Compounds and Methods of Treatment	EPIX DELAWARE, INC.
PRX-3140	08100-006903	PCT	Abandoned	200804951	200804951	6-Jun-2008	South Africa	29-Apr-2009	Compositions and Methods for Treating CNS Disorders	EPIX DELAWARE, INC.
PRX-3140	08100-006901	PCT	Abandoned	9413528		6-Oct-2005	Taiwan		Thienopyridone Compounds and Methods of Treatment	EPIX DELAWARE, INC.
PRX-3140	08100-006903	ORD	Abandoned	9514148		9-May-2006	Taiwan		Thienopyridone Compounds and Methods of Treatment	EPIX DELAWARE, INC.
PRX-3140	08100-006901	ORD	Abandoned	104899			Thailand		Thienopyridone Compounds and Methods of Treatment	EPIX DELAWARE, INC.
PRX-3140	08100-006900	ORD	Abandoned	60105651		8-Nov-2006	Thailand		Compositions and Methods for Treating CNS Disorders	EPIX DELAWARE, INC.
PRX-3140	08100-006900	PCT	Abandoned	TT/A/2006/00227		13-Nov-2006	Trinidad and Tobago		Thienopyridone Compounds and Methods of Treatment	EPIX DELAWARE, INC.
PRX-3140	08100-006901	PCT	Abandoned	TT/A/2007/00248		8-Oct-2007	Trinidad and Tobago		Thienopyridone Compounds and Methods of Treatment	EPIX DELAWARE, INC.
PRX-3140	08100-006903	PCT	Abandoned	TT/A/2008/00090		29-Apr-2008	Trinidad and Tobago		Compositions and Methods for Treating CNS Disorders	EPIX DELAWARE, INC.
PRX-3140	08100-006901	PCT	Abandoned	200704997		6-Oct-2005	Ukraine		Thienopyridone Compounds and Methods of Treatment	EPIX DELAWARE, INC.
PRX-3140	08100-006903	PCT	Abandoned			8-Nov-2006	Ukraine		Compositions and Methods for Treating CNS Disorders	EPIX DELAWARE, INC.







CLORONRGIN	08100-009400	PCT	Issued	610860 S 3		HK1108388	4-Sep-2006	Hong Kong	13-Feb-2008	Water-Soluble SHPS as Novel Alkylating Agents	VION PHARMACEUTICALS, INC.
CLORONRGIN	08100-009400	PCT	Abandoned	2006-533183			12-Dec-2005	Japan		Water-Soluble SHPS as Novel Alkylating Agents	VION PHARMACEUTICALS, INC.
CLORONRGIN	08100-009400	ORD	Completed	PCT/US2004/015547			18-May-2004	PCT	15-Feb-2005	Water-Soluble SHPS as Novel Alkylating Agents	VION PHARMACEUTICALS, INC.
CLORONRGIN	08100-009401	ORD	Issued	10461282	8685695		13-Jun-2003	U.S.		Water-Soluble SHPS as Novel Alkylating Agents	VION PHARMACEUTICALS, INC.
CLORONRGIN	08100-009401	Div	Abandoned	103601990			27-Sep-2004	U.S.		Water-Soluble SHPS as Novel Alkylating Agents	VION PHARMACEUTICALS, INC.
TAPET	08100-009500	ORD	Issued	121454397	81261095	73714	27-May-2009	Australia	9/27/2011	Process for the synthesis of anti-hepatitis agent V192401114	VION PHARMACEUTICALS, INC.
TAPET	08100-009500	PCT	Issued	69334300			9-Apr-2002	Brazil	23-Mar-2006	Compositions and methods for tumor-targeted delivery of effector molecules	VION PHARMACEUTICALS, INC.
TAPET	08100-009500	PCT	Abandoned	P10014491-6			4-Apr-2002	China		Compositions and methods for tumor-targeted delivery of effector molecules	VION PHARMACEUTICALS, INC.
TAPET	08100-009500	PCT	Abandoned	23956565			2-Apr-2002	China		Compositions and methods for tumor-targeted delivery of effector molecules	VION PHARMACEUTICALS, INC.
TAPET	08100-009500	Div	Abandoned	8197141			4-Jun-2002	China		Compositions and methods for tumor-targeted delivery of effector molecules	VION PHARMACEUTICALS, INC.
TAPET	08100-009501	PCT	Abandoned	210091E-11			10-May-2002	Europe		Compositions and methods for tumor-targeted delivery of effector molecules	VION PHARMACEUTICALS, INC.
TAPET	08100-009500	PCT	Abandoned	310822012	397794.4		12-Nov-2003	Hong Kong		Compositions and methods for tumor-targeted delivery of effector molecules	VION PHARMACEUTICALS, INC.
TAPET	08100-009500	PCT	Abandoned	148953			27-Mar-2002	Japan		Compositions and methods for tumor-targeted delivery of effector molecules	VION PHARMACEUTICALS, INC.
TAPET	08100-009500	PCT	Abandoned	2001-528592			4-Apr-2002	Japan		Compositions and methods for tumor-targeted delivery of effector molecules	VION PHARMACEUTICALS, INC.
TAPET	08100-009500	PCT	Abandoned	2002-2004371			4-Apr-2002	Korea		Compositions and methods for tumor-targeted delivery of effector molecules	VION PHARMACEUTICALS, INC.
TAPET	08100-009500	PCT	Abandoned	P446202/003934		518354	3-Apr-2002	Mexico	09-Jun-2005	Compositions and methods for tumor-targeted delivery of effector molecules	VION PHARMACEUTICALS, INC.
TAPET	08100-009500	ORD	Abandoned	518354			12-Apr-2002	New Zealand		Compositions and methods for tumor-targeted delivery of effector molecules	VION PHARMACEUTICALS, INC.
TAPET	08100-009500	ORD	Completed	PCT/US2002/23242			24-Aug-2000	PCT		Compositions and methods for tumor-targeted delivery of effector molecules	VION PHARMACEUTICALS, INC.
TAPET	08100-009500	ORD	Abandoned	20201817.4		88111	24-Aug-2000	Singapore		Compositions and methods for tumor-targeted delivery of effector molecules	VION PHARMACEUTICALS, INC.
TAPET	08100-009501	Div	Abandoned	10738423	9992896		16-Dec-2003	U.S.	08-Nov-2005	Compositions and methods for tumor-targeted delivery of effector molecules	VION PHARMACEUTICALS, INC.
TAPET	08100-009502	Div	Issued	11482344	7452531		17-Mar-2005	U.S.	18-Nov-2008	Compositions and methods for tumor-targeted delivery of effector molecules	VION PHARMACEUTICALS, INC.
TAPET	08100-009503	ORD	Abandoned	11254122			20-Oct-2006	U.S.		Compositions and methods for tumor-targeted delivery of effector molecules	VION PHARMACEUTICALS, INC.
TAPET	08100-009504	CON	Abandoned	111627743			26-Jan-2007	U.S.		Non-invasive Tumor Imaging by Tumor-Targeted Beadles	NANOTHERAPEUTICS, INC.
TAPET	08100-009500	ORD	Abandoned	09679454			4-Oct-2009	U.S.		Compositions and Methods for Delivery of an Agent Using Altemusolol Salmeterol Containing Phage	NANOTHERAPEUTICS, INC.
TAPET	08100-009500	ORD	Abandoned	09645418			24-Aug-2000	U.S.		Compositions and Methods for Delivery of an Agent Using Altemusolol Salmeterol Containing Phage	NANOTHERAPEUTICS, INC.
TAPET	08100-009501	CON	Abandoned	10076117			13-Feb-2002	U.S.		Compositions and Methods for Delivery of an Agent Using Altemusolol Salmeterol Containing Phage	VION PHARMACEUTICALS, INC.
TAPET	08100-009502	CON	Abandoned	10790386			1-Mar-2004	China		Compositions and Methods for Delivery of an Agent Using Altemusolol Salmeterol Containing Phage	VION PHARMACEUTICALS, INC.
TRI	08100-009800	ORD	Abandoned	2.0041E+11			2-Jan-2004	China		Cancer Treatment Comprising Taspine	VION PHARMACEUTICALS, INC.
TRI	08100-009801138	Div	Abandoned	2.0101E+11			16-Sep-2010	China		Cancer Treatment Comprising Taspine	VION PHARMACEUTICALS, INC.
TRI	08100-009800	EPIC	Abandoned	199875714	728165		14-May-1999	Australia	19-Apr-2001	Process for the synthesis of ribonucleoside reduce inhibitors of 3'AP and 3'AMP	VION PHARMACEUTICALS, INC.
TRI	08100-009800	PCT	Abandoned	P19868410-6			16-Nov-1999	Brazil		Process for the synthesis of ribonucleoside reduce inhibitors of 3'AP and 3'AMP	VION PHARMACEUTICALS, INC.
TRI	08100-009800	PCT	Abandoned	2298970			12-Nov-1999	Canada		Process for the synthesis of ribonucleoside reduce inhibitors of 3'AP and 3'AMP	VION PHARMACEUTICALS, INC.
TRI	08100-009800	PCT	Abandoned	98805147.8	9880517.8		15-Nov-1999	China	13-Aug-2003	Process for the synthesis of ribonucleoside reduce inhibitors of 3'AP and 3'AMP	VION PHARMACEUTICALS, INC.
TRI	08100-009800	PCT	Abandoned	9880344.1			8-Dec-1999	Europe		Process for the synthesis of ribonucleoside reduce inhibitors of 3'AP and 3'AMP	VION PHARMACEUTICALS, INC.
TRI	08100-009800	PCT	Abandoned	104783.7	HK102587		29-Jul-2000	Hong Kong	21-Nov-2003	Process for the synthesis of ribonucleoside reduce inhibitors of 3'AP and 3'AMP	VION PHARMACEUTICALS, INC.
TRI	08100-009800	PCT	Abandoned	10-548514			12-Nov-1999	Japan		Process for the synthesis of ribonucleoside reduce inhibitors of 3'AP and 3'AMP	VION PHARMACEUTICALS, INC.
TRI	08100-009800	PCT	Abandoned	10-1991016375			15-Nov-1999	Korea		Process for the synthesis of ribonucleoside reduce inhibitors of 3'AP and 3'AMP	VION PHARMACEUTICALS, INC.
TRI	08100-009800	PCT	Abandoned	9910427	220387		12-Nov-1999	Mexico	12-May-2004	Process for the synthesis of ribonucleoside reduce inhibitors of 3'AP and 3'AMP	VION PHARMACEUTICALS, INC.
TRI	08100-009800	ORD	Completed	PCT/US98009803			14-Dec-1998	PCT		Process for the synthesis of ribonucleoside reduce inhibitors of 3'AP and 3'AMP	VION PHARMACEUTICALS, INC.
TRI	08100-009800	PCT	Abandoned	99128808			14-Dec-1999	Russia		Process for the synthesis of ribonucleoside reduce inhibitors of 3'AP and 3'AMP	VION PHARMACEUTICALS, INC.
TRI	08100-009800	ORD	Issued	02856559	53893576		15-May-1997	U.S.	05-Feb-1999	Process for the synthesis of ribonucleoside reduce inhibitors of 3'AP and 3'AMP	VION PHARMACEUTICALS, INC.
TRI	08100-009100	PCT	Abandoned	7484098	773748		8-Dec-1999	Australia	19-Apr-2001	Process for the synthesis of ribonucleoside reduce inhibitors of 3'AP and 3'AMP	VION PHARMACEUTICALS, INC.
TRI	08100-009100	PCT	Abandoned	P10809353-8			16-Nov-1999	Brazil		Process for the synthesis of ribonucleoside reduce inhibitors of 3'AP and 3'AMP	VION PHARMACEUTICALS, INC.
TRI	08100-009100	PCT	Abandoned	2290617			12-Nov-1999	Canada		Process for the synthesis of ribonucleoside reduce inhibitors of 3'AP and 3'AMP	VION PHARMACEUTICALS, INC.
TRI	08100-009100	PCT	Abandoned	98805148.6			15-Nov-1999	China		Process for the synthesis of ribonucleoside reduce inhibitors of 3'AP and 3'AMP	VION PHARMACEUTICALS, INC.

PATENT

REEL: 035236 FRAME: 0955



TRI	08100-0091001139	DIV	Issued	2,008E-11	ZL 200810085427,9	14-May-1988	China	22-Jan-14	Producing Forms of Ribonucleotide Reductase Inhibitors 3-AP and 3-AMP	VION PHARMACEUTICALS, INC.
TRI	08100-0091001	ORO	Abandoned	989224.6	EP0908285	14-May-1988	Europe		Producing Forms of Ribonucleotide Reductase Inhibitors 3-AP and 3-AMP	VION PHARMACEUTICALS, INC.
TRI	08100-009100	ORO	Abandoned	104761.6		29-Jul-2000	Hong Kong		Producing Forms of Ribonucleotide Reductase Inhibitors 3-AP and 3-AMP	VION PHARMACEUTICALS, INC.
TRI	08100-009100	PCT	Abandoned	10-48484		11-Nov-1989	Japan		Producing Forms of Ribonucleotide Reductase Inhibitors 3-AP and 3-AMP	VION PHARMACEUTICALS, INC.
TRI	08100-009100	ORO	Abandoned	1939-7070585		15-Nov-1989	Korea		Producing Forms of Ribonucleotide Reductase Inhibitors 3-AP and 3-AMP	VION PHARMACEUTICALS, INC.
TRI	08100-009100	ORO	Completed	PCT/US98/009750		14-May-1988	PCT		Producing Forms of Ribonucleotide Reductase Inhibitors 3-AP and 3-AMP	VION PHARMACEUTICALS, INC.
TRI	08100-009100	PCT	Abandoned	9917242		14-Dec-1989	Russia	27-Feb-2003	Producing Forms of Ribonucleotide Reductase Inhibitors 3-AP and 3-AMP	VION PHARMACEUTICALS, INC.
TRI	08100-009100	ORO	Issued	08185-858		15-May-1997	U.S.	16-Jun-1998	Producing Forms of Ribonucleotide Reductase Inhibitors 3-AP and 3-AMP	VION PHARMACEUTICALS, INC.
TRI	08100-009200	PCT	Issued	200211725		3-Mar-2011	Australia	13-Oct-2008	Modified producing forms of AP/AMP	VION PHARMACEUTICALS, INC.
TRI	08100-009200	PCT	Abandoned	P0174583-3		11-Apr-2003	Brazil		Modified producing forms of AP/AMP	VION PHARMACEUTICALS, INC.
TRI	08100-009200	PCT	Issued	2423220		19-Mar-2003	Canada	03-Jan-2012	Modified producing forms of AP/AMP	VION PHARMACEUTICALS, INC.
TRI	08100-009200	PCT	Issued	1818923.8		4-Apr-2003	China	26-Oct-2005	Modified producing forms of AP/AMP	VION PHARMACEUTICALS, INC.
TRI	08100-009200	PCT	Issued	1978900.8		8-May-2003	Europe	25-May-2011	Modified producing forms of AP/AMP	VION PHARMACEUTICALS, INC.
TRI	08100-009200	PCT	Issued	1978900.8		15-Oct-2001	France	25-May-2011	Modified producing forms of AP/AMP	VION PHARMACEUTICALS, INC.
TRI	08100-009200	PCT	Issued	1978900.8		15-Oct-2001	Great Britain	25-May-2011	Modified producing forms of AP/AMP	VION PHARMACEUTICALS, INC.
TRI	08100-009200	PCT	Issued	1978900.8		13-May-2001	Ireland	25-May-2011	Modified producing forms of AP/AMP	VION PHARMACEUTICALS, INC.
TRI	08100-009200	PCT	Issued	1978900.8		15-Oct-2001	Germany	25-May-2011	Modified producing forms of AP/AMP	VION PHARMACEUTICALS, INC.
TRI	08100-009200	PCT	Issued	1978900.8		15-Oct-2001	Germany	25-May-2011	Modified producing forms of AP/AMP	VION PHARMACEUTICALS, INC.
TRI	08100-009200	PCT	Issued	410089.4		10-Feb-2004	Hong Kong	05-Jan-2008	Modified producing forms of AP/AMP	VION PHARMACEUTICALS, INC.
TRI	08100-009200	PCT	Issued	2002-533885		15-Oct-2001	Japan	01-Apr-2008	Modified producing forms of AP/AMP	VION PHARMACEUTICALS, INC.
TRI	08100-009200	PCT	Abandoned	10-5003-700578		11-Apr-2003	Korea		Modified producing forms of AP/AMP	VION PHARMACEUTICALS, INC.
TRI	08100-009200	PCT	Abandoned	PA/0203-003161		10-Apr-2003	Mexico		Modified producing forms of AP/AMP	VION PHARMACEUTICALS, INC.
TRI	08100-009200	ORO	Completed	PCT/US01/023085		15-Oct-2001	PCT		Modified producing forms of AP/AMP	VION PHARMACEUTICALS, INC.
TRI	08100-009200	PCT	Abandoned	2003118538		12-May-2003	Russia		Modified producing forms of AP/AMP	VION PHARMACEUTICALS, INC.
TRI	08100-009200	ORO	Issued	09877.659		15-Oct-2001	U.S.	01-Oct-2002	Modified producing forms of AP/AMP	VION PHARMACEUTICALS, INC.
FDAC	08100-009800	PCT	Abandoned	32381197		11-Dec-1988	Australia	23-Mar-2000	Process for high-yield dastereoselective synthesis of diacyonucleotides	VION PHARMACEUTICALS, INC.
FDAC	08100-009800	PCT	Abandoned	P1 9709785-3		14-Dec-1988	Brazil		Process for high-yield dastereoselective synthesis of diacyonucleotides	VION PHARMACEUTICALS, INC.
FDAC	08100-009800	PCT	Abandoned	22831.60		11-Dec-1988	China		Process for high-yield dastereoselective synthesis of diacyonucleotides	VION PHARMACEUTICALS, INC.
FDAC	08100-009800	ORO	Abandoned	9719517.4		14-Dec-1988	China		Process for high-yield dastereoselective synthesis of diacyonucleotides	VION PHARMACEUTICALS, INC.
FDAC	08100-009800	PCT	Abandoned	97927916.3		12-Jan-1989	Europe		Process for high-yield dastereoselective synthesis of diacyonucleotides	VION PHARMACEUTICALS, INC.
FDAC	08100-009800	PCT	Abandoned	100023.1		4-Jan-2000	Hong Kong		Process for high-yield dastereoselective synthesis of diacyonucleotides	VION PHARMACEUTICALS, INC.
FDAC	08100-009800	PCT	Abandoned	5016571988		14-Dec-1988	Japan		Process for high-yield dastereoselective synthesis of diacyonucleotides	VION PHARMACEUTICALS, INC.
FDAC	08100-009800	PCT	Abandoned	98-0710188		11-Dec-1988	Korea		Process for high-yield dastereoselective synthesis of diacyonucleotides	VION PHARMACEUTICALS, INC.
FDAC	08100-009800	ORO	Issued	00663.674		14-Jan-1986	U.S.	21-Dec-1989	Process for high-yield dastereoselective synthesis of diacyonucleotides	VION PHARMACEUTICALS, INC.
FDAC	08100-009800	ORO	Completed	PCT/US1997/009486		2-Jun-1997	PCT		Process for high-yield dastereoselective synthesis of diacyonucleotides	VION PHARMACEUTICALS, INC.
PROVISIONAL	08100-010300000	PRO	Completed	13822.687		14-Mar-2013	U.S.		Compositions and Methods for Oral Delivery of Encapsulated Dihydratediaminopentamethanesulfoxal Particles	VION PHARMACEUTICALS, INC.
PROVISIONAL	08100-010300110	PRO	Pending	201232491		14-Mar-2013	Australia		Compositions and Methods for Oral Delivery of Encapsulated Dihydratediaminopentamethanesulfoxal Particles	VION PHARMACEUTICALS, INC.
PROVISIONAL	08100-010300131	PRO	Pending	2.887.701		14-Mar-2013	Canada		Compositions and Methods for Oral Delivery of Encapsulated Dihydratediaminopentamethanesulfoxal Particles	VION PHARMACEUTICALS, INC.
PROVISIONAL	08100-010300155	PRO	Pending	137301118		14-Mar-2013	Canada		Compositions and Methods for Oral Delivery of Encapsulated Dihydratediaminopentamethanesulfoxal Particles	VION PHARMACEUTICALS, INC.
PROVISIONAL	08100-010300195	PRO	Pending	PCT/US01/001336		18-Sep-2014	Japan		Compositions and Methods for Oral Delivery of Encapsulated Dihydratediaminopentamethanesulfoxal Particles	VION PHARMACEUTICALS, INC.
PROVISIONAL	08100-0999000	ORO	Unfiled				U.S.		Compositions and Methods for Oral Delivery of Encapsulated 3-Amino-2-Carboxyethyl-L-Asparagine Particles	VION PHARMACEUTICALS, INC.
PROVISIONAL	08100-0999000	PRO	Expired	60248.557		22-Jan-2002	U.S.		METHOD OF PULSED LASER ASSISTED SURFACE	NANOHERAPEUTICS, INC.
PROVISIONAL	08100-0999000	ORO	Expired	60282.322		22-Jan-2002	U.S.		METHOD OF COLLECTING AND ANALYZING HUMAN BREATH	NANOHERAPEUTICS, INC.
PROVISIONAL	08100-0999000	PRO	Expired	60015.316		11-May-2007	U.S.		Method of collecting and analyzing air samples	NANOHERAPEUTICS, INC.
PROVISIONAL	08100-0999000	PRO	Expired	60089.672		3-Sep-2007	U.S.		Compositions and Methods for Improved Delivery and Absorption of Basic Compounds	NANOHERAPEUTICS, INC.
PROVISIONAL	08100-0999000	PRO	Inactive				U.S.		Compositions and Methods for Improved Delivery and Absorption of Basic Compounds	NANOHERAPEUTICS, INC.

PATENT

REEL: 035236 FRAME: 0956

PROVISIONAL	08100-600400	PRO	Expired	60966,045	7-Nov-2007	U.S.	Composition and Methods for Oral Delivery	NANOTHERAPEUTICS, INC.
PROVISIONAL	08100-600600	PRO	Pending	61099,858	16-Aug-2008	U.S.	Topical Hydrogel Composition	NANOTHERAPEUTICS, INC.
PROVISIONAL	08100-600800	PRO	Inactive	61108,518	26-Oct-2008	U.S.	Process of Modifying Particles Using Filtration and Compositions Produced Thereby	NANOTHERAPEUTICS, INC.
PROVISIONAL	08100-600700	PRO	Completed	60971,882	17-Mar-2004	U.S.	Theopyridone compounds and methods of treatment	NANOTHERAPEUTICS, INC.
PROVISIONAL	08100-600800	PRO	Completed	60738,004	17-Nov-2005	U.S.	5-HT3 Modulating compounds and uses thereof	NANOTHERAPEUTICS, INC.
PROVISIONAL	08100-600900	PRO	Pending	61119,838	3-Dec-2008	U.S.	Biocys Compounds and Methods of Making and Using Same	NANOTHERAPEUTICS, INC.
PROVISIONAL	08100-601000	PRO	Expired	60873,790	24-Mar-2004	U.S.	Nasal Powder, Vaccine Compositions and Uses Thereof	CARRINGTON LABORATORIES, INC.
PROVISIONAL	08100-601100	PRO	Expired	60874,354	12-Dec-2006	U.S.	Purification of Influenza Viral Antigens	CARRINGTON LABORATORIES, INC.
PROVISIONAL	08100-601200	PRO	Completed	60465,757	23-Apr-2003	U.S.	Method for Reducing Transmission of Nosocomial Pathogens in a Health Care Facility	CARRINGTON LABORATORIES, INC.
PROVISIONAL	08100-601300	PRO	Completed	60408,595	6-Sep-2002	U.S.	Method for Preventing Gram-Positive Bacteremia	CARRINGTON LABORATORIES, INC.
PROVISIONAL	08100-601400	PRO	Completed	60469,803	12-May-2003	U.S.	Use of Ramoplanin to Treat Diseases Associated with the Use of Antibiotics	CARRINGTON LABORATORIES, INC.
PROVISIONAL	08100-601500	PRO	Completed	61032,184	10-Aug-2010	U.S.	Compositions and Methods for Oral Delivery of Encapsulated Diethylaminoethanolamine Derivatives	NANOTHERAPEUTICS, INC.
PROVISIONAL	08100-601600	PRO	Pending	60663,454	11-Mar-2005	U.S.	Allylthyminease Assays	NANOTHERAPEUTICS, INC.
PROVISIONAL	08100-601700	PRO	Completed	60157,500	18-Mar-2005	U.S.	Composition and Method for the Tumor-Targeted Delivery of Anti-Angiogenic Factors	NANOTHERAPEUTICS, INC.
PROVISIONAL	08100-601701	PRO	Completed	60157,581	4-Oct-1999	U.S.	Composition and Method for the Tumor-Targeted Delivery of Anti-Angiogenic Factors	NANOTHERAPEUTICS, INC.
PROVISIONAL	08100-601702	PRO	Completed	60157,637	4-Oct-1999	U.S.	Composition and Method for the Tumor-Targeted Delivery of Anti-Angiogenic Factors	NANOTHERAPEUTICS, INC.
PROVISIONAL	08100-601800	PRO	Completed	60240,529	13-Oct-2000	U.S.	Modified Prodrug forms of AP/AMP	NANOTHERAPEUTICS, INC.
PROVISIONAL	08100-601900	PRO	Completed	60631,828	24-May-2007	U.S.	Methods of Synthesizing VPE/10M	NANOTHERAPEUTICS, INC.
PROVISIONAL	08100-601901	PRO	Completed	61128,975	27-Mar-2008	U.S.	Method of treating ischemia, reperfusion myocardial infarction and other cardiovascular conditions and disease states	NANOTHERAPEUTICS, INC.
PROVISIONAL	08100-602000	PRO	Completed	60549,950	4-Mar-2004	U.S.	Method of treating ischemia, reperfusion myocardial infarction and other cardiovascular conditions and disease states	NANOTHERAPEUTICS, INC.
PROVISIONAL	08100-602001	PRO	Completed	60651,981	10-Mar-2004	U.S.	Method of treating ischemia, reperfusion myocardial infarction and other cardiovascular conditions and disease states	NANOTHERAPEUTICS, INC.
PROVISIONAL	08100-602100	PRO	Completed	60549,958	3-Mar-2004	U.S.	Method of treating ischemia, reperfusion myocardial infarction and other cardiovascular conditions and disease states	NANOTHERAPEUTICS, INC.
PROVISIONAL	08100-602101	PRO	Completed	60660,357	10-Mar-2005	U.S.	Novel Hydrazone and Imine Compounds as Anti-Cancer Agents	NANOTHERAPEUTICS, INC.
PROVISIONAL	08100-602102	PRO	Completed	60660,356	10-Mar-2005	U.S.	Novel Hydrazone and Imine Compounds as Anti-Cancer Agents	NANOTHERAPEUTICS, INC.
PROVISIONAL	08100-602103	PRO	Completed	60781,886	13-Mar-2006	U.S.	Novel Hydrazone and Imine Compounds as Anti-Cancer Agents	NANOTHERAPEUTICS, INC.
PROVISIONAL	08100-602104	PRO	Completed	60606,886	14-Mar-2007	U.S.	Novel Hydrazone and Imine Compounds as Anti-Cancer Agents	NANOTHERAPEUTICS, INC.
PROVISIONAL	08100-602200	PRO	Completed	60616,623	21-Sep-2004	U.S.	Prostate bearing prodrugs of strobil mycotoxins as hypoxia selective antitumor agents	NANOTHERAPEUTICS, INC.
PROVISIONAL	08100-602201	PRO	Completed	60616,419	1-Oct-2004	U.S.	Prostate bearing prodrugs of strobil mycotoxins as hypoxia selective antitumor agents	NANOTHERAPEUTICS, INC.
PROVISIONAL	08100-602202	PRO	Completed	60616,500	6-Oct-2004	U.S.	Prostate bearing prodrugs of strobil mycotoxins as hypoxia selective antitumor agents	NANOTHERAPEUTICS, INC.
PROVISIONAL	08100-602300	PRO	Completed	60616,388	12-Apr-2005	U.S.	Hypoxia-selective agents as anti-cancer agents	NANOTHERAPEUTICS, INC.
PROVISIONAL	08100-602400	PRO	Completed	60157,620	4-Oct-1999	U.S.	Non-invasive Tumor Imaging by Tumor-Targeted Beadlets	NANOTHERAPEUTICS, INC.
PROVISIONAL	08100-602500	PRO	Completed	60150,828	26-Aug-1999	U.S.	Non-invasive Tumor Imaging by Tumor-Targeted Beadlets	NANOTHERAPEUTICS, INC.
PROVISIONAL	08100-602600	PRO	Completed	60252,259	28-Jan-2002	177	Compositions and Methods for Delivery of an Agent Using Alternating Schizomicin Containing Phage	NANOTHERAPEUTICS, INC.
PROVISIONAL	08100-602700	PRO	Completed	61614,333	22-Mar-2012	U.S.	Methods for Treating Cancer by Administering Tumor-Targeted Beadlets and an Immunomodulatory Agent	NANOTHERAPEUTICS, INC.
PROVISIONAL	08100-602800	PRO	Expired	61771,873	3-Mar-2013	U.S.	Compositions and Methods for Oral Delivery of Encapsulated Dabiravirin/Interferon-beta Particles	NANOTHERAPEUTICS, INC.
PROVISIONAL	8100-602900000	PRO	Abandoned			U.S.	Compositions and Methods for Oral Delivery of Encapsulated Dabiravirin/Interferon-beta Particles	NANOTHERAPEUTICS, INC.
PROVISIONAL	08100-603000000	PRO	Pending	61048,085	5-Mar-2014	U.S.	Compositions and Methods for Oral Delivery of Encapsulated 3-Amino-1,2-Carboxyethyl-2-Deoxyribose Particles	NANOTHERAPEUTICS, INC.
PROVISIONAL	08100-603100000	PRO	Pending	61080,370	16-Apr-2014	U.S.	Methods of Treatment of C-Difficile Spores With Ramoplanin	NANOTHERAPEUTICS, INC.

PATENT